Events & Meetings / News - July 8, 2020
In the past two decades, a combination of scientific breakthrough coupled with strong incentives systems brought about great progress for rare disease patients. The number of medicines approved in Europe to treat rare diseases since 2000 increased from 8 to 169. However, with 95% of… read more
News / Press Releases - July 7, 2020
On the verge of the publication of the EU industrial strategy in March, EUCOPE shared the expectations and ambitions of its membership for a coherent strategy that harness Europe’s untapped potential: small and medium biopharma. The mission letter from President von der Leyen to Commissioner Kyriakides… read more
Events & Meetings / News - June 25, 2020
EUCOPE invites you to an online discussion on the future of rare diseases innovation to the benefit of patients in Europe. Entitled ‘How can Europe remain at the forefront of innovation to the benefit of patients with rare diseases?’, the event will take place online… read more
News - June 16, 2020
The European Commission just opened the public consultation on its proposed pharmaceutical strategy for the EU. In the Commission’s words, the strategy intends to ‘address the current issues of access, availability and affordability of medicines, while still promoting sustainable innovation and support EU industry to… read more
EUCOPE Resources / News - June 2, 2020
EUCOPE examined with great interest the European Commission’s Pharmaceutical Strategy Roadmap. We welcome the European Commission’s acknowledgement of the crucial role played by the pharmaceutical sector in the economy of the EU, as well as the creation of a future-proof, knowledge-intensive European Union. We share… read more
EUCOPE Resources / News - May 15, 2020
The 10th European Conference on Rare Diseases (ECRD), the largest patient-led event on rare diseases and orphan products, presented an excellent opportunity for exchange among the patient community and experts from various backgrounds. The conference allowed EUCOPE to share the key findings of the study… read more
News - April 8, 2020
The COVID-19 pandemic creates an extraordinary situation for all stakeholders. EUCOPE members are particularly concerned with the impact the COVID-19 crisis created on clinical development. Delay of patients’ access to innovative treatment The delay caused by the pandemic in drug development is in particular concerning… read more
EUCOPE Resources / News - April 6, 2020
In a study commissioned by EUCOPE, the Office of Health Economics (OHE) assessed the extent to which the Orphan Medicinal Products (OMPs) Regulation (2000/018) has successfully incentivised companies to invest in research and development of OMPs. The study also puts forward an analysis of the… read more
News / Press Releases - March 10, 2020
EUCOPE asks the European Commission to put research at the heart of its Pharmaceutical Strategy The European Commission’s Pharmaceutical Strategy for Europe must: Provide ambitious measures to foster research in rare diseases and other disease areas for which we currently have no cure. Harness the… read more
News - February 28, 2020
On Rare Diseases Day, EUCOPE is delighted to host an interview with Laurence Woollard, patient expert and rare disease advocate, to discuss with him the importance of an engaged community and the opportunities and challenges new treatments can bring. See Laurence’s Q&A on our blog.
